Compounds > 4'-(9-acridinylamino)methanesulfonanilide
Page last updated: 2024-12-07

4'-(9-acridinylamino)methanesulfonanilide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4'-(9-acridinylamino)methanesulfonanilide: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID107678
CHEMBL ID9806
SCHEMBL ID6115003
MeSH IDM0061127

Synonyms (22)

Synonym
53478-38-9
methanesulfonamide, n-(4-(9-acridinylamino)phenyl)-
brn 0496528
methanesulfonanilide, 4'-(9-acridinylamino)-
sn 11838
n-(4-(9-acridinylamino)phenyl)methanesulfonamide
ccris 4546
4'-(9-acridinylamino)methanesulfonanilide
n-(p-(9-acridinylamino)phenyl)methanesulfonamide
9-(4-(methanesulfonamido)anilino)acridine
NEURO_000088
NCI60_001123
CHEMBL9806
n-[4-(acridin-9-ylamino)phenyl]methanesulfonamide
unii-jm63707o3j
jm63707o3j ,
sn-11838
SCHEMBL6115003
DTXSID80201659
4'-(acridin-9-ylamino)methanesulphonanilide
9-[4-(methanesulfonamido)anilino]acridine
Q27281577

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"3 to 150 mg/sq m/day; (b) toxicity in the form of stomatitis, vomiting, and phlebitis occurred at dosage levels of 125 to 150 mg/sq m/day; and (c) oncolytic effects were observed in 13 of 24 patients."( Phase I clinical and pharmacokinetic study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide in children with cancer.
Dahl, GV; Evans, WE; Pratt, CB; Rivera, G; Yee, GC, 1980)		0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (81)

Assay IDTitleYearJournalArticle
AID26599Dissociation constant (pKa)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
On the significance of clusters in the graphical display of structure-activity data.
AID150215In vivo dose of drug needed for a percentage increase of 50% in life span of tumor-bearing mice compared to untreated controls after inoculation of 10e6 P388 leukemia cells1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Potential antitumor agents. 42. Structure-activity relationships for acridine-substituted dimethyl phosphoramidate derivatives of 9-anilinoacridine.
AID119953Dose of drug given intraperitoneally on a qd 1-5 schedule that provides the highest ILS value in mice bearing 10E6 ip inoculated L1210 leukemia cells1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Potential antitumor agents. 41. Analogues of amsacrine with electron-donor substituents in the anilino ring.
AID1148475Toxicity in ip dosed BDF1 mouse allografted with mouse P388 cells administered qd for 5 days1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents.
AID1133946Antitumor activity against mouse L1210 cells intraperitoneally xenografted in ip dosed C3H/DBA2 F1 hybrid mouse assessed as increase in host lifespan administered daily for 5 days starting 24 hrs post-tumor implantation1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Potential antitumor agents. 22. Latentiated congeners of the 4'-(9-acridinylamino)methanesulfonanilides.
AID1150557Antitumor activity against mouse L1210 cells allografted in C3H/DBA2 F1 mouse assessed as increase in life span at optimum dose, ip qd administered for 5 days relative to control1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Potential antitumor agents. 17. 9-Anilino-10-methylacridinium salts.
AID1148474Antitumor activity against mouse L1210 cells allografted in ip dosed BDF1 mouse at optimum dose administered qd for 5 days relative to control1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents.
AID132896Percent increase in the life span of treated mice over a group of control mice injected with p388 tumor alone when administered intraperitoneally (66) as a solution in 0.1 mL of 30%,v/v, ethanol/water1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Potential antitumor agents. 39. Anilino ring geometry of amsacrine and derivatives: relationship to DNA binding and antitumor activity.
AID152520In vivo tumor cell selectivity (ILSmax values)for percentage increase in life span of treated animals over that of P388 tumor bearing untreated control animals1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Potential antitumor agents. 42. Structure-activity relationships for acridine-substituted dimethyl phosphoramidate derivatives of 9-anilinoacridine.
AID1148473Antitumor activity against mouse P388 cells allografted in ip dosed BDF1 mouse at optimum dose administered qd for 5 days relative to control1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents.
AID1132612Logarithmic function of the retardation factor value of compound by reverse phase chromatography analysis1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Potential antitumor agents. 27. Quantitative structure--antileukemic (L1210) activity relationships for the omega-[4-(9-acridinylamino)phenyl]alkanoic acids.
AID117342Percentage increase in life span of drug-treated tumor bearing controls was determined1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Potential antitumor agents. 41. Analogues of amsacrine with electron-donor substituents in the anilino ring.
AID1150101Antitumor activity against mouse L1210 cells allografted in ip dosed C3H X DBA2 F1 mouse assessed as optimum dose required to cause greatest life extension administered as qd for 5 days1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Potential antitumor agents. 24. Dicationic analogues of the 4'-(9-acridinylamino)alkanesulfonanilides.
AID152668In vivo inhibition of P388 in mice for optimal (highest nonacutely toxic) dose (OD)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Potential antitumor agents. 42. Structure-activity relationships for acridine-substituted dimethyl phosphoramidate derivatives of 9-anilinoacridine.
AID1150100Ionization constant, pKa of the compound by UV spectrophotometric analysis1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Potential antitumor agents. 24. Dicationic analogues of the 4'-(9-acridinylamino)alkanesulfonanilides.
AID139092Drug dose in (mg/kg)/day to provide an increase in life span of 40% was determined1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Potential antitumor agents. 33. Quantitative structure--activity relationships for mutagenic activity and antitumor activity of substituted 4'-(9-acridinylamino)methanesulfonanilide derivatives.
AID1148375Antitumor activity against mouse L1210 cells transfected in C3H/DBA2 F1 mouse assessed as increase in life span at optimum dose administered ip qd for 5 days relative to control1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Potential antitumor agents. 26. Anionic congeners of the 9-anilinoacridines.
AID1148476Toxicity in ip dosed BDF1 mouse allografted with mouse L1210 cells administered qd for 5 days1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents.
AID26375Ionisation constant (pKa)1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring.
AID1132613Toxicity in ip dosed C3H/DBA2F1 hybrid mouse allografted with mouse L1210 cells administered for 5 days measured up to 8 days1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Potential antitumor agents. 27. Quantitative structure--antileukemic (L1210) activity relationships for the omega-[4-(9-acridinylamino)phenyl]alkanoic acids.
AID153878Percentage increase in life span was measured for P-388 cells in culture after intraperitoneal administration of a dose of 150 mg/kg1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Potential antitumor agents. 37. Organophosphorus derivatives of 9-anilinoacridine.
AID210614Compound concentration in mole/kg/day lethal to 10% of mice1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Potential antitumor agents. 36. Quantitative relationships between experimental antitumor activity, toxicity, and structure for the general class of 9-anilinoacridine antitumor agents.
AID1133943Half life of the compound in 0.1 M mercaptoethanol buffer at pH 7.4 at 37 degC by thiolytic assay1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Potential antitumor agents. 22. Latentiated congeners of the 4'-(9-acridinylamino)methanesulfonanilides.
AID162407Antitumor activity as association constant for DNA binding to poly (dA.dT)1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Potential antitumor agents. 37. Organophosphorus derivatives of 9-anilinoacridine.
AID201226The mutagenic effectiveness, lowest molar concentration required for a constant proportion of revertant colonies (chosen as 50 per 10E8 bacteria)1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Potential antitumor agents. 33. Quantitative structure--activity relationships for mutagenic activity and antitumor activity of substituted 4'-(9-acridinylamino)methanesulfonanilide derivatives.
AID1133944Toxicity in ip dosed mouse assessed as optimum dose that providing maximum increase in life span administered qd for 1 to 5 days1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Potential antitumor agents. 22. Latentiated congeners of the 4'-(9-acridinylamino)methanesulfonanilides.
AID116709Drug dose that is lethal to 10% of animals was measured1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring.
AID24209Association constant for binding to poly [d(G-C)]1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring.
AID153025Optimal dose administered intraperitoneally in1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Potential antitumor agents. 39. Anilino ring geometry of amsacrine and derivatives: relationship to DNA binding and antitumor activity.
AID25311Acid dissociation constant was determined1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Potential antitumor agents. 39. Anilino ring geometry of amsacrine and derivatives: relationship to DNA binding and antitumor activity.
AID1150556Antitumor activity against mouse L1210 cells allografted in ip dosed C3H/DBA2 F1 mouse assessed as optimum dose required to increase in maximum life span administered as qd for 5 days1976Journal of medicinal chemistry, Jun, Volume: 19, Issue:6
Potential antitumor agents. 17. 9-Anilino-10-methylacridinium salts.
AID20511Lipophilicity (Rm) (liquid chromatography)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Potential antitumor agents. 42. Structure-activity relationships for acridine-substituted dimethyl phosphoramidate derivatives of 9-anilinoacridine.
AID26528Binding affinity towards poly[d(A-T)] (fluorometric method)1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Potential antitumor agents. 42. Structure-activity relationships for acridine-substituted dimethyl phosphoramidate derivatives of 9-anilinoacridine.
AID1134704Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as increase in life span at optimal dose administered qd from day 1 to 5 of challenge relative to control1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Potential antitumor agents. 25. Azalogues of the 4'-(9-acridinylamino) methanesulfonanilides.
AID1149747Antileukemic activity against ip implanted mouse L1210 cells in C3H/DBA2 F1 hybrid hybrid mouse assessed as increase life span treated ip after 24 hrs after tumor inoculation and continued for 5 days1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Potential antitumor agents. 23. 4'-(9-Acridinylamino)alkanesulfonanilide congeners bearing hydrophilic functionality.
AID1132614Antitumor activity against mouse L1210 cells allografted in C3H/DBA2F1 hybrid mouse assessed as maximum increase of host life span administered as ip for 5 days relative to control1978Journal of medicinal chemistry, May, Volume: 21, Issue:5
Potential antitumor agents. 27. Quantitative structure--antileukemic (L1210) activity relationships for the omega-[4-(9-acridinylamino)phenyl]alkanoic acids.
AID1134708Antitumor activity against mouse L1210 cells allografted in ip dosed mouse assessed as dose required for maximum increase in life span administered qd from day 1 to 5 of challenge1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Potential antitumor agents. 25. Azalogues of the 4'-(9-acridinylamino) methanesulfonanilides.
AID1134706Lipophilic-hydrophilic balance, Rm of the compound by reversed-phase partition chromatography1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Potential antitumor agents. 25. Azalogues of the 4'-(9-acridinylamino) methanesulfonanilides.
AID1134705Ionization constant, pKa of the compound in 20% DMF-buffer mixture by UV spectrophotometry1977Journal of medicinal chemistry, Oct, Volume: 20, Issue:10
Potential antitumor agents. 25. Azalogues of the 4'-(9-acridinylamino) methanesulfonanilides.
AID1148373Lipopholic-hydrophilic balance, Rm of the compound by reversed-phase chromatography1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Potential antitumor agents. 26. Anionic congeners of the 9-anilinoacridines.
AID1150102Antitumor activity against mouse L1210 cells allografted through ip in C3H X DBA2 F1 mouse assessed as increase in life span at optimum dose, ip qd administered for 5 days relative to control1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Potential antitumor agents. 24. Dicationic analogues of the 4'-(9-acridinylamino)alkanesulfonanilides.
AID20508Chromatographic measure of drug lipophilicity1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Potential antitumor agents. 39. Anilino ring geometry of amsacrine and derivatives: relationship to DNA binding and antitumor activity.
AID1149743Half life in mouse L1210 cells allografted C3H/DBA2 F1 hybrid hybrid mouse1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Potential antitumor agents. 23. 4'-(9-Acridinylamino)alkanesulfonanilide congeners bearing hydrophilic functionality.
AID96646Concentration for inhibiting the growth of L1210 cells by 50% over 3 days was determined1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Potential antitumor agents. 37. Organophosphorus derivatives of 9-anilinoacridine.
AID1150103Antitumor activity against mouse L1210 cells allografted through sc in C3H X DBA2 F1 mouse assessed as increase in life span at optimum dose, ip qd administered for 5 days relative to control1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Potential antitumor agents. 24. Dicationic analogues of the 4'-(9-acridinylamino)alkanesulfonanilides.
AID1148477Lipophilic-hydrophilic balance, Rm of the compound by reversed-phase chromatographic analysis1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents.
AID235013In vitro therapeutic index value is the ratio between IC50 values of [J] and [P]1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Synthesis and in vitro evaluation of 9-anilino-3,6-diaminoacridines active against a multidrug-resistant strain of the malaria parasite Plasmodium falciparum.
AID98819Drug concentration in mole/kg/day providing 50% extension of life in intraperitoneally implanted leukemia L1210 mice.1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Potential antitumor agents. 36. Quantitative relationships between experimental antitumor activity, toxicity, and structure for the general class of 9-anilinoacridine antitumor agents.
AID54456Binding constant to poly (dA-dT) was determined in calf thymus DNA by a fluorometric method1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Potential antitumor agents. 39. Anilino ring geometry of amsacrine and derivatives: relationship to DNA binding and antitumor activity.
AID1149744Retardation factor, Rm of the compound by reversed phase partition chromatography1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Potential antitumor agents. 23. 4'-(9-Acridinylamino)alkanesulfonanilide congeners bearing hydrophilic functionality.
AID25641Half life of the drug was determined in the presence of 2-mercaptoethanol1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Potential antitumor agents. 39. Anilino ring geometry of amsacrine and derivatives: relationship to DNA binding and antitumor activity.
AID98490Inhibitory concentration to reduce the growth of L1210 cells by 50% after 70 hr. 1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Redox chemistry of the 9-anilinoacridine class of antitumor agents.
AID25575Dissociation constant in aqueous DMF.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Potential antitumor agents. 41. Analogues of amsacrine with electron-donor substituents in the anilino ring.
AID26756DNA binding dissociation constant as KD1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Interactions of antitumor drugs with natural DNA: 1H NMR study of binding mode and kinetics.
AID201364Mutagenic efficiency, measured as the concentration providing 50% inhibition of Salmonella Typhimurium strain TA 1537 growth in drug induced-mutant colonies1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Potential antitumor agents. 33. Quantitative structure--activity relationships for mutagenic activity and antitumor activity of substituted 4'-(9-acridinylamino)methanesulfonanilide derivatives.
AID55124Binding constant for DNA by ethidium bromide displacement1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Potential antitumor agents. 41. Analogues of amsacrine with electron-donor substituents in the anilino ring.
AID139101Percent increase in life span in L1210 assay at the LD10 dose1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Potential antitumor agents. 33. Quantitative structure--activity relationships for mutagenic activity and antitumor activity of substituted 4'-(9-acridinylamino)methanesulfonanilide derivatives.
AID116415Maximum percent increase in life span of mice was determined by L1210 assay1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring.
AID19849Maximum reversion frequency1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
On the significance of clusters in the graphical display of structure-activity data.
AID25559Ionization constant (pKa)1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Potential antitumor agents. 36. Quantitative relationships between experimental antitumor activity, toxicity, and structure for the general class of 9-anilinoacridine antitumor agents.
AID1133945Antitumor activity against mouse L1210 cells subcutaneously xenografted in ip dosed C3H/DBA2 F1 hybrid mouse assessed as increase in host lifespan administered daily for 5 days starting 24 hrs post-tumor implantation1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Potential antitumor agents. 22. Latentiated congeners of the 4'-(9-acridinylamino)methanesulfonanilides.
AID1148374Antitumor activity against mouse L1210 cells transfected in ip dosed C3H/DBA2 F1 mouse qd administered for 5 days1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Potential antitumor agents. 26. Anionic congeners of the 9-anilinoacridines.
AID46149Inhibitory concentration against ethidium binding to DNA1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring.
AID20524Relative measure (Rm) of lipophilic/hydrophilic balance from partition chromatography1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Potential antitumor agents. 33. Quantitative structure--activity relationships for mutagenic activity and antitumor activity of substituted 4'-(9-acridinylamino)methanesulfonanilide derivatives.
AID98699Reduce in the cell count when drug added to the murine L1210 leukemia cell cultures for 70 h1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
Potential antitumor agents. 39. Anilino ring geometry of amsacrine and derivatives: relationship to DNA binding and antitumor activity.
AID134224In vivo toxicity (qd 1-5), determined using the intraperitoneal implantation of L1210 leukemia cells in mice1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Potential antitumor agents. 33. Quantitative structure--activity relationships for mutagenic activity and antitumor activity of substituted 4'-(9-acridinylamino)methanesulfonanilide derivatives.
AID26064Ionization constant (pKa)1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Potential antitumor agents. 33. Quantitative structure--activity relationships for mutagenic activity and antitumor activity of substituted 4'-(9-acridinylamino)methanesulfonanilide derivatives.
AID150694Concentration for inhibiting the growth of P-388 cells by 50% over 3 days was determined1982Journal of medicinal chemistry, Oct, Volume: 25, Issue:10
Potential antitumor agents. 37. Organophosphorus derivatives of 9-anilinoacridine.
AID1133942Lipophilic-hydrophilic balance, Rm of the compound by reversed-phase partition chromatography1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Potential antitumor agents. 22. Latentiated congeners of the 4'-(9-acridinylamino)methanesulfonanilides.
AID1148471Displacement of ethidium bromide from calf thymus DNA by spectrofluorometric analysis1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Potenial antitumor agents. 28. Deoxyribonucleic acid polyintercalating agents.
AID95454Concentration required to reduce growth of human jurkat leukemia cells to 50% of control cultures, determined using a 72 hr continuous exposure1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Synthesis and in vitro evaluation of 9-anilino-3,6-diaminoacridines active against a multidrug-resistant strain of the malaria parasite Plasmodium falciparum.
AID1148372Dissociation constant, basic pKa of the compound by UV spectrophotometry1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Potential antitumor agents. 26. Anionic congeners of the 9-anilinoacridines.
AID24208Association constant for binding to poly [d(A-T)]1981Journal of medicinal chemistry, Feb, Volume: 24, Issue:2
Potential antitumor agents. 34. Quantitative relationships between DNA binding and molecular structure for 9-anilinoacridines substituted in the anilino ring.
AID101091In vitro concentration required to inhibit the growth of L1210 cells in culture by 50% following a 48 hr exposure.1984Journal of medicinal chemistry, Mar, Volume: 27, Issue:3
Potential antitumor agents. 41. Analogues of amsacrine with electron-donor substituents in the anilino ring.
AID201229Concentration of drug needed to kill Salmonella Typhimurium strain TA 1537 grown on histidine-enriched medium1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Potential antitumor agents. 33. Quantitative structure--activity relationships for mutagenic activity and antitumor activity of substituted 4'-(9-acridinylamino)methanesulfonanilide derivatives.
AID158039Inhibitory concentration IC50 against Plasmodium falciparum K1 by [3H]hypoxanthine uptake over 24 hr1994Journal of medicinal chemistry, May-13, Volume: 37, Issue:10
Synthesis and in vitro evaluation of 9-anilino-3,6-diaminoacridines active against a multidrug-resistant strain of the malaria parasite Plasmodium falciparum.
AID100306Dose of the drug (mol /kg) providing a 50% life extension in L1210 assays when given at qd 1-5 schedule. 1987Journal of medicinal chemistry, Mar, Volume: 30, Issue:3
Redox chemistry of the 9-anilinoacridine class of antitumor agents.
AID26537log K value (Logarithm of DNA-affinity association constant)1986Journal of medicinal chemistry, Apr, Volume: 29, Issue:4
On the significance of clusters in the graphical display of structure-activity data.
AID96632In vitro test for 50% reduction of cell number (of control) after 70 hr incubation with cultures of murine L1210 leukemia cells1984Journal of medicinal chemistry, Aug, Volume: 27, Issue:8
Potential antitumor agents. 42. Structure-activity relationships for acridine-substituted dimethyl phosphoramidate derivatives of 9-anilinoacridine.
AID1149746Antileukemic activity against sc implanted mouse L1210 cells in C3H/DBA2 F1 hybrid hybrid mouse assessed as increase life span treated ip after 24 hrs after tumor inoculation and continued for 5 days1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Potential antitumor agents. 23. 4'-(9-Acridinylamino)alkanesulfonanilide congeners bearing hydrophilic functionality.
AID1149745Toxicity in sc implanted mouse L1210 cells allografted C3H/DBA2 F1 hybrid hybrid mouse assessed as optimum dose required to increase life span treated ip after 24 hrs after tumor inoculation and continued for 5 days1977Journal of medicinal chemistry, Aug, Volume: 20, Issue:8
Potential antitumor agents. 23. 4'-(9-Acridinylamino)alkanesulfonanilide congeners bearing hydrophilic functionality.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-199031 (93.94)18.7374
1990's2 (6.06)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.74 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.03%)6.00%
Case Studies2 (6.06%)4.05%
Observational0 (0.00%)0.25%
Other30 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
quinacrine
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.		1.9610acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound		antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
phosphonoacetic acid
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.. phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.		3.0610monocarboxylic acid;
phosphonic acids		antiviral agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor
ametantrone
ametantrone: RN given refers to parent cpd; structure		1.9610
amsacrine
Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.		3.97140acridines;
aromatic ether;
sulfonamide		antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		2.3820aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
stallimycin
[no description available]		1.9610
ellipticine
ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11.		1.9610indole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound;
polycyclic heteroarene		antineoplastic agent;
plant metabolite
ethidium
Ethidium: A trypanocidal agent and possible antiviral agent that is widely used in experimental cell biology and biochemistry. Ethidium has several experimentally useful properties including binding to nucleic acids, noncompetitive inhibition of nicotinic acetylcholine receptors, and fluorescence among others. It is most commonly used as the bromide.. ethidium : The fluorescent compound widely used in experimental cell biology and biochemistry to reveal double-stranded DNA and RNA.		1.9610phenanthridinesfluorochrome;
intercalator
hycanthone
Hycanthone: Potentially toxic, but effective antischistosomal agent, it is a metabolite of LUCANTHONE.. hycanthone : A thioxanthen-9-one compound having a hydroxymethyl substituent at the 1-position and a 2-[(diethylamino)ethyl]amino substituent at the 4-position. It was formerly used (particularly as the monomethanesulfonic acid salt) as a schistosomicide for individual or mass treatement of infection with Schistosoma haematobium and S. mansoni, but due to its toxicity and concern about possible carcinogenicity, it has been replaced by other drugs such as praziquantel.		1.9610thioxanthenesmutagen;
schistosomicide drug
ifosfamide
[no description available]		3.0610ifosfamidesalkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic
mefloquine hydrochloride
[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol : An organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4.		1.9810organofluorine compound;
piperidines;
quinolines;
secondary alcohol
mitoxantrone
Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.		1.9610dihydroxyanthraquinoneanalgesic;
antineoplastic agent
tilorone
Tilorone: An antiviral agent used as its hydrochloride. It is the first recognized synthetic, low-molecular-weight compound that is an orally active interferon inducer, and is also reported to have antineoplastic and anti-inflammatory actions.. tilorone : A member of the class of fluoren-9-ones that is 9H-fluoren-9-one which is substituted by a 2-(diethylamino)ethoxy group at positions 2 and 7. It is an interferon inducer and a selective alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonist. Its hydrochloride salt is used as an antiviral drug.		1.9610aromatic ether;
diether;
fluoren-9-ones;
tertiary amino compound		anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
interferon inducer;
nicotinic acetylcholine receptor agonist
aspartic acid
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.. aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent. L-aspartic acid : The L-enantiomer of aspartic acid.		3.0610aspartate family amino acid;
aspartic acid;
L-alpha-amino acid;
proteinogenic amino acid		Escherichia coli metabolite;
mouse metabolite;
neurotransmitter
methyltestosterone
Methyltestosterone: A synthetic hormone used for androgen replacement therapy and as an hormonal antineoplastic agent (ANTINEOPLASTIC AGENTS, HORMONAL).. methyltestosterone : A 17beta-hydroxy steroid that is testosterone bearing a methyl group at the 17alpha position.		3.061017beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
enone		anabolic agent;
androgen;
antineoplastic agent
medroxyprogesterone acetate
[no description available]		3.061020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester		adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive
aminacrine
Aminacrine: A highly fluorescent anti-infective dye used clinically as a topical antiseptic and experimentally as a mutagen, due to its interaction with DNA. It is also used as an intracellular pH indicator.. 9-aminoacridine : An aminoacridine that is acridine in which the hydrogen at position 9 is replaced by an amino group. A fluorescent dyd and topical antiseptic agent, it is used (usually as the hydrochloride salt) in eye drops for the treatment of superficial eye infections.		5.25170aminoacridines;
primary amino compound		acid-base indicator;
antiinfective agent;
antiseptic drug;
fluorescent dye;
MALDI matrix material;
mutagen
proflavine
Proflavine: Topical antiseptic used mainly in wound dressings.. 3,6-diaminoacridine : An aminoacridine that is acridine that is substituted by amino groups at positions 3 and 6. A slow-acting bacteriostat that is effective against many Gram-positive bacteria (but ineffective against spores), its salts were formerly used for treatment of burns and infected wounds.		1.9610aminoacridinesantibacterial agent;
antiseptic drug;
carcinogenic agent;
chromophore;
intercalator
acridines
Acridines: Compounds that include the structure of acridine.. acridine : A polycyclic heteroarene that is anthracene in which one of the central CH groups is replaced by a nitrogen atom.		2.3620acridines;
mancude organic heterotricyclic parent;
polycyclic heteroarene		genotoxin
medroxyprogesterone
[no description available]		3.061017alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone		contraceptive drug;
progestin;
synthetic oral contraceptive
ethidium bromide
[no description available]		1.9610organic bromide saltgeroprotector;
intercalator;
trypanocidal drug
9-anilinoacridine
[no description available]		3.0550
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		1.9710delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
daunorubicin
Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.		2.6530aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones		antineoplastic agent;
bacterial metabolite
razoxane
Razoxane: An antimitotic agent with immunosuppressive properties.		3.0610N-alkylpiperazine
etoposide
[no description available]		3.0610beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound		antineoplastic agent;
DNA synthesis inhibitor
elliptinium
elliptinium: synthetic ellipticine deriv; RN given refers to parent cpd; structure given in first source		2.3620carbazoles
4-(9-acridinylamino)aniline
4-(9-acridinylamino)aniline: RN given refers to parent cpd		3.2160
9-(4-methylanilino)-acridine
9-(4-methylanilino)-acridine: RN given refers to parent cpd; structure in first source		2.6530
norharman
norharman: RN given refers to parent cpd. beta-carboline : The parent compound of the beta-carbolines, a tricyclic structure comprising an indole ring system ortho- fused to C-3 and C-4 of a pyridine ring.		1.9610beta-carbolines;
mancude organic heterotricyclic parent		fungal metabolite;
marine metabolite
dimidium
dimidium: RN given refers to parent cpd		1.9610
5-iminodaunorubicin
5-iminodaunorubicin: RN given refers to parent cpd		1.9610
9-hydroxyellipticine
9-hydroxyellipticine: RN given refers to parent cpd. 9-hydroxyellipticine : A organic heterotetracyclic compound that is ellipticine in which the hydrogen at position 9 has been replaced by a hydroxy group.		1.9610organic heterotetracyclic compound;
organonitrogen heterocyclic compound		antineoplastic agent
4'-(9-acridinylamino)methanesulfon-o-anisidide
4'-(9-acridinylamino)methanesulfon-o-anisidide: 30-90 times less potent in killing L1210 cells & 200 times less potent in producing single-strand breaks in DNA than m-AMSA; RN given refers to parent cpd; structure in first source		2.6630
pyronaridine
[no description available]		1.9810aminoquinoline
3,6-diamino-9-(4-(methylsulfonyl)aminophenyl)aminoacridine
[no description available]		2.3720
sn 6999
SN 6999: structure given in first source; RN given refers to parent cpd		1.9610
2,9-dimethyl-beta-carbolinium
2,9-dimethyl-beta-carbolinium: inhibits mitochondrial respiration		1.9610
mitonafide
[no description available]		1.9610
dactinomycin
Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)		2.3720actinomycinmutagen
jp-1302
[no description available]		1.9610
tamoxifen
[no description available]		3.0610stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
quinine
[no description available]		1.9810cinchona alkaloidantimalarial;
muscle relaxant;
non-narcotic analgesic
bisantrene
[no description available]		1.9610
stilbamidine
stilbamidine: RN given refers to parent cpd		1.9610
diacetyldiphenylurea bisguanylhydrazone
diacetyldiphenylurea bisguanylhydrazone: antineoplastic agent particularly effective as an antileukemic agent; has been shown to be active against leukemia L1210 in mice; minor descriptor (75-86); on-line & INDEX MEDICUS search CARBANILIDES (75-86); RN given refers to parent cpd		1.9610
n,n-(4-xylylidene)bisaminoguanidine
N,N-(4-xylylidene)bisaminoguanidine: RN in Chemline for di-HCl: 7044-24-8; RN for unspecified HCl: 62580-72-7. N,N'-(p-xylylidene)bis(aminoguanidine) : A guanidine derivative comprised of two carbamimidamido (guanidino) groups, each linked via one of their amino nitrogens to the imino nitrogens of 1,4-phenylenedimethanimine.		1.9610
nad
NAD(1-) : An anionic form of nicotinamide adenine dinucleotide arising from deprotonation of the two OH groups of the diphosphate moiety.		1.9610organophosphate oxoanioncofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite
arginine
Teniposide: A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.. teniposide : A furonaphthodioxole that is a synthetic derivative of podophyllotoxin with anti-tumour activity; causes single- and double-stranded breaks in DNA and DNA-protein cross-links and prevents repair by topoisomerase II binding.		3.0610
ConditionIndicatedRelationship StrengthStudiesTrials
Leukemia L 1210
[description not available]		04.09160
Experimental Leukemia
[description not available]		01.9510
Leukemia P388
An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.		02.8840
Benign Neoplasms
[description not available]		02.8710
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.8710
Leucocythaemia
[description not available]		01.9510
Osteogenic Sarcoma
[description not available]		01.9510
Angioma, Sclerosing
[description not available]		01.9510
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		01.9510
Neuroblastoma
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)		01.9510
Rhabdomyosarcoma
A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)		01.9510
Osteosarcoma
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)		01.9510
Histiocytoma, Benign Fibrous
A benign tumor composed, wholly or in part, of cells with the morphologic characteristics of HISTIOCYTES and with various fibroblastic components. Fibrous histiocytomas can occur anywhere in the body. When they occur in the skin, they are called dermatofibromas or sclerosing hemangiomas. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 5th ed, p1747)		01.9510
Mast-Cell Sarcoma
A unifocal malignant tumor that consists of atypical pathological MAST CELLS without systemic involvement. It causes local destructive growth in organs other than in skin or bone marrow.		01.9610
Hypokalemia
Abnormally low potassium concentration in the blood. It may result from potassium loss by renal secretion or by the gastrointestinal route, as by vomiting or diarrhea. It may be manifested clinically by neuromuscular disorders ranging from weakness to paralysis, by electrocardiographic abnormalities (depression of the T wave and elevation of the U wave), by renal disease, and by gastrointestinal disorders. (Dorland, 27th ed)		01.9610
Leukemia, Lymphocytic
[description not available]		01.9610
Leukemia, Lymphoid
Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.		01.9610
Ventricular Fibrillation
A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.		01.9610
Malignant Melanoma
[description not available]		02.3620
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.3620